Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prostate brachytherapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Prostate brachytherapy. Displaying page 1 of 1.
    EudraCT Number: 2008-007028-25 Sponsor Protocol Number: ON/2008/2781 Start Date*: 2010-08-17
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: A Randomised Controlled Trial to Determine the Effect of Decapeptyl on Reduction of Prostate Volume Pre-Radiotherapy Compared with Standard Therapy (Zoladex)
    Medical condition: Enrolled patients will be those with a diagnosis of prostate cancer who require radiotherapy to the prostate, with medical castration by means of Luteneising Hormone Releasing Hormone analogue (LRH...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004351-29 Sponsor Protocol Number: 2008-02-IMP-5 Start Date*: 2008-12-18
    Sponsor Name:HEXAL AG
    Full Title: OPEN LABEL, MULTICENTER STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF GOSERELIN 10.8 mg IMPLANT HEXAL IN PATIENTS WITH ADVANCED HORMONE DEPENDENT PROSTATE CANCER
    Medical condition: Palliative treatment of advanced hormone dependent prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-003382-18 Sponsor Protocol Number: BED-PSMA-302 Start Date*: 2020-05-25
    Sponsor Name:Blue Earth Diagnostics Ireland Ltd.
    Full Title: A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with suspected prostate cancer recurrence b...
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004235-24 Sponsor Protocol Number: ABX-CT-303 Start Date*: 2021-06-09
    Sponsor Name:ABX GmbH
    Full Title: Phase III study of [18F]PSMA-1007 positron emission tomography for the detection of prostate cancer lesions in patients with biochemical recurrence after previous definitive treatment for localized...
    Medical condition: Suspicion of prostate cancer recurrence or persistence after previous definitive treatment, based on American Society for Radiation Oncology (ASTRO) criteria of 3 consecutive PSA rises and/or ASTRO...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000625-37 Sponsor Protocol Number: BED-004 Start Date*: 2015-08-28
    Sponsor Name:Blue Earth Diagnostics Limited
    Full Title: A phase 3, open-label study to assess the clinical utility of fluciclovine (18F) PET/CT in patients with prostate cancer with biochemical recurrence after radical treatment
    Medical condition: Prostate cancer with biochemical recurrence after radical treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005073-37 Sponsor Protocol Number: I-1409 Start Date*: 2015-02-02
    Sponsor Name:Department of Nuclear Medicine, Aalborg University Hospital
    Full Title: 68Ga-PSMA PET/CT for detection of recurrent prostate cancer: Comparison with 18F-fluoride PET/CT, MRI and DW-MRI
    Medical condition: Patients diagnosed with biochemical (PSA) relapse following curative intended treatment (defined as radical prostatectomy or radiotherapy, either by external beam radiotherapy or low- or high-dose ...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    17.1 100000004848 10036223 Positron emission tomography LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001634-28 Sponsor Protocol Number: MDV3100-13(C3431004) Start Date*: 2015-04-24
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressi...
    Medical condition: Patients with high-risk nonmetastatic prostate cancer progressing after definitive therapy (radical prostatectomy or radiotherapy or both).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) DK (Trial now transitioned) DE (Completed) SK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-000808-40 Sponsor Protocol Number: 2004-27-IMP-2 Start Date*: 2005-01-13
    Sponsor Name:Hexal AG
    Full Title: Randomized, open label, multi-center, phase III study on pharmacokinetics, pharmacodynamics, efficacy and safety of Goserelin 1M Implant HEXAL in patients with advanced prostatic cancer in comparis...
    Medical condition: Palliative treatment of advanced prostatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002873-62 Sponsor Protocol Number: 2005-34-IMP-2 Start Date*: 2006-02-15
    Sponsor Name:HEXAL AG
    Full Title: RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE II STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF BUSERELIN 3M IMPLANT HEXAL IN PATIENTS WITH ADVANCED PROSTATIC CANCER IN COMPARISON...
    Medical condition: Palliative treatment of advanced prostatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-001279-36 Sponsor Protocol Number: 2005-01-IMP-2 Start Date*: 2005-08-24
    Sponsor Name:Hexal AG
    Full Title: RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE II STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF GOSERELIN 3M IMPLANT HEXAL IN PATIENTS WITH ADVANCED PROSTATIC CANCER IN COMPARISON...
    Medical condition: Palliative treatment of advanced prostatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017798-39 Sponsor Protocol Number: PROVAX study Start Date*: 2010-07-08
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study)
    Medical condition: Prostate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated level...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001200 Adenocarcinoma of the prostate stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000121-37 Sponsor Protocol Number: 2020-PSMA Start Date*: 2020-06-09
    Sponsor Name:CYCLOPHARMA
    Full Title: A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
    Medical condition: Patients with histopathologically confirmed prostate adenocarcinoma per original diagnosis and subsequent definitive therapy, with first biochemical recurrence
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020825-42 Sponsor Protocol Number: RTOG0815 Start Date*: 2010-11-08
    Sponsor Name:Radiation Therapy Oncology Group
    Full Title: A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER
    Medical condition: intermediate risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004749-41 Sponsor Protocol Number: NEO-ONE Start Date*: 2011-12-13
    Sponsor Name:TweeSteden hospital
    Full Title: The effects of neoadjuvant hormonal therapy on the course of PSA and testosterone in patients with low and intermediate-risk prostate carcinoma (NEO-ONE); A randomized controlled trial
    Medical condition: Localized prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003873-41 Sponsor Protocol Number: 14-23-16/07 Start Date*: 2015-07-09
    Sponsor Name:MAASTRO Clinic
    Full Title: Non invasive imaging of tumor hypoxia with [18F]HX4 Positron-Emission-Tomography (PET): A phase II trial
    Medical condition: Eligible patients with histologically/cytologically proven primary tumors of the prostate, esophagus, brain or rectum or metastatic disease to the brain (originating from breast, lung or colorectal...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004397-99 Sponsor Protocol Number: MBCC28040 Start Date*: 2014-06-17
    Sponsor Name:Instituto Tecnológico PET, S.A.U. (ITP)
    Full Title: A Phase III Clinical Trial to evidence the safety and efficacy of the radio-drug 18f-Fluorocholine (18F-FCH), using Positron Emission Tomography (PET) for the diagnosis of the prostate carcinoma in...
    Medical condition: Prostate Carcinoma in patients with biochemical relapse.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-001128-31 Sponsor Protocol Number: 13-23 Start Date*: 2014-09-23
    Sponsor Name:Cancer Trials Ireland
    Full Title: Phase II Single-arm Study evaluating Neo-adjuvant (pre-radical radiotherapy) Abiraterone acetate (plus prednisolone) and Gonadotropin-Releasing Hormone (GnRH) agonist in high risk localised prostat...
    Medical condition: High-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004412-55 Sponsor Protocol Number: C.HO.SE. Start Date*: 2013-04-15
    Sponsor Name:AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO
    Full Title: Cabazitaxel in relapsed high-risk HOrmone-SEnsitive prostate cancer patients. A multicentric Randomized phase II study. C.HO.SE. Trial
    Medical condition: Relapsed high-risk hormone-sensitive prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003739-32 Sponsor Protocol Number: 1801 Start Date*: 2020-02-28
    Sponsor Name:Actuate Therapeutics Inc
    Full Title: Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignan...
    Medical condition: Refractory Hematologic Malignancies or Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004952-14 Sponsor Protocol Number: 0209-01 Start Date*: 2021-07-07
    Sponsor Name:Constellation Pharmaceuticals, Inc.
    Full Title: A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Tumors
    Medical condition: advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, ovarian clear cell cancer, endometrial carcinoma, GCB-DLBCL, small cell lu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) ES (Temporarily Halted)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 14:20:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA